CD70 and neoplasm: To investigate the ability of CD70 CAR-TOAd−GFP cells to eradicate pre-established tumors in vivo, an NCG mouse tumor burden model was constructed (intracranial orthotopic injection of U251 cells, with control group mice having an approximate survival time of 40 days after the initiation of treatment), followed by intratumoral injection of CD70 CAR-TOAd−GFP (Fig. 2B).